How has been the historical performance of Aurobindo Pharma?

Answer:The historical performance of Aurobindo Pharma shows a steady growth in net sales and profit over the years, with significant fluctuations in profit margins and expenses. Breakdown: Aurobindo Pharma's net sales have consistently increased from INR 19,563.55 crore in March 2019 to INR 31,723.73 crore in March 2025. The total operating income followed a similar trend, reaching INR 31,723.73 crore in March 2025, up from INR 24,855.38 crore in March 2023. The company's operating profit (PBDIT) also saw growth, rising to INR 7,204.64 crore in March 2025 from INR 4,009.23 crore in March 2023, indicating improved operational efficiency. However, the profit before tax showed fluctuations, peaking at INR 7,398.96 crore in March 2021 and then declining to INR 5,097.98 crore in March 2025. Profit after tax increased to INR 3,515.26 crore in March 2025 from INR 1,939.32 crore in March 2023. The company's earnings per share (EPS) improved to INR 60.02 in March 2025, up from INR 32.90 in March 2023. Total assets grew from INR 28,764.54 crore in March 2020 to INR 48,492.01 crore in March 2025, while total liabilities also increased, reflecting a rise in total debt from INR 5,561.97 crore in March 2020 to INR 7,941.68 crore in March 2025. Cash flow from operating activities improved significantly to INR 3,924 crore in March 2025, compared to INR 2,386 crore in March 2023, contributing to a net cash inflow of INR 2,178 crore in March 2025. Overall, Aurobindo Pharma has demonstrated resilience and growth in its financial performance over the years.